Exchange: NYSEArca·Updated 06:44 AM EDT
News
all
press releases
RARE Stock Heads For Record Low: Angelman Trial Miss Leads To Wall Street Downgrades – This Analyst Sees Another Problem Ahead
William Blair downgraded Ultragenyx to ‘Market Perform’ from ‘Outperform,’ stating the miss could have negative implications for Ultragenyx’s other Angelman syndrome trial.
Stocktwits
More News
Why Did RARE Stock Slump 46% After-Hours?
Ultragenyx said the late-stage Aspire study of apazunersen, also known as GTX-102, did not meet its primary goal or key backup goal in a late-stage trial.
Stocktwits
QURE Stock Fades After AMT-130 filing — But William Blair Sees 58% Upside
uniQure announced it had submitted a Biologics License Application to the FDA seeking accelerated approval of ifezuntirgene inilparvovec, or AMT-130, for Huntington’s disease.
Stocktwits
Sellas Gears Up To Present Preclinical SLS009 Data For Pancreatic Cancer At Major Oncology Conference
Three abstracts evaluating SLS009 have been accepted for poster presentations at the AACR Conference on Pancreatic Cancer later in September.
Stocktwits
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
Zacks
Why Is CAPR Stock Rising Today? Piper Sandler Says Risk-Reward Favors Owning Stock Into FDA Decision
Piper Sandler upgraded Capricor to ‘Overweight’ from ‘Neutral’ and sharply raised the price target to $25, a roughly 150% upside potential from current levels.
Stocktwits
SLS, IBRX Stocks Post August Gains: Eli Lilly’s Latest $2.9B Deal Has Retail Traders Bracing For An ‘M&A Rampage’
Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.
Stocktwits
VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3
Investors are now awaiting results from an early-stage study of VK2735 testing different ways to keep weight off after an initial course of treatment.
Stocktwits
SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger
An AstraZeneca sales executive called the Phase 3 Regal trial a “game changer” for AML patients in their first or second complete remission.
Stocktwits
BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset
CEO Gayer told CNBC in an interview that the company is now profitable and plans to use that cash to invest in other rare-disease medicines.
Stocktwits

Advertisement|Remove ads.